Summarized by Masters of Longevity from Nature - Biotechnology.
Patient-derived teratomas are presented as a humanized experimental platform to test cell- and gene-based strategies for restoring dystrophin in DMD models, offering a way to evaluate therapeutic delivery, editing, and myogenic maturation in a patient-specific context.
Key Takeaways
- Patient-derived teratomas from DMD iPS cells produced skeletal muscle-like tissue suitable for therapeutic testing.
- Ex vivo transplantation of adenine base editor–corrected myogenic progenitors partially restored shorter dystrophin isoforms but did not reproducibly recover full-length Dp427m.
- Local lipid nanoparticle delivery of adenine base editor mRNA achieved dose-dependent editing and restoration of shorter dystrophin isoforms including Dp71.
